METiS is a cutting-edge startup operating in the biotechnology sector, specifically in the development of novel therapeutics. The company leverages advanced technologies such as Artificial Intelligence (AI), Machine Learning (ML), and Molecular Dynamics (MD) to innovate in the small molecule, biologics, and advanced nucleic acid spaces. In simpler terms, they use AI and ML to create new drugs and therapies.

Their primary focus is on the discovery of unique Lipid Nanoparticles (LNPs) through AI and high-throughput in vivo screening. LNPs are tiny particles used to deliver drugs to specific parts of the body. METiS has developed LNPs that can target multiple organ systems, demonstrating high delivery efficiency and clean safety profiles in animal models.

METiS' business model revolves around building a proprietary predictive AI platform to redefine drug discovery. They aim to create a robust and targeted delivery system for small molecules, RNA, and gene therapies. By exploring the uncharted territory of AI and new biology, they hope to provide clinical value to patients.

The company is open to partnerships focused on their AI- and ML-developed nanoparticles. They also offer collaboration opportunities on external programs, indicating a business model that includes strategic alliances and partnerships.

In terms of revenue generation, while the specifics are not explicitly stated, it can be inferred that METiS likely makes money through partnerships, licensing deals, and potentially the sale of their novel therapeutics once they reach the market.

Keywords: Biotechnology, Artificial Intelligence, Machine Learning, Molecular Dynamics, Drug Discovery, Lipid Nanoparticles, Small Molecules, RNA Therapies, Gene Therapies, Strategic Partnerships.